PROCEPT BioRobotics (NASDAQ:PRCT) Announces Quarterly Earnings Results, Misses Expectations By $0.07 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) released its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.07), FiscalAI reports. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company had revenue of $98.29 million for the quarter, compared to analysts’ expectations of $100.52 million. During the same period in the previous year, the firm earned ($0.38) earnings per share. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• PROCEPT reported third-quarter revenue of $98.3 million, up 18% year over year, with U.S. procedures rising 22% and U.S. handpiece and consumable revenue increasing 21%. Handpiece pricing remained strong, and the company said field inventory had normalized.
• Procedure growth remains challenged by weaker utilization on legacy AquaBeam systems as surgeons shift cases to HYDROS; HYDROS accounts performed more than 35% more procedures than legacy accounts. Management expects about 54,000 procedures for 2026, within its guidance range, but reaching that level implies the strongest sequential procedure growth of the year in Q4.
• The company placed 62 HYDROS systems, including 20 replacements, at an average U.S. selling price of about $495,000. Although greenfield placements fell short of expectations in Q3 due largely to timing, management maintained that it expects to meet or exceed its initial full-year system targets and said capital demand remains healthy.
• The net loss widened to $26.5 million from $21.4 million a year earlier, and adjusted EBITDA loss increased to $9.8 million from $7.4 million as operating expenses rose with investment. Management expects positive adjusted EBITDA in Q4 and described approximately 20% revenue growth in 2027 as a planning baseline, while noting that formal guidance will come later.

PROCEPT BioRobotics Trading Down 3.6%

Shares of NASDAQ PRCT traded down $0.77 during midday trading on Thursday, hitting $20.89. The stock had a trading volume of 1,568,591 shares, compared to its average volume of 1,501,645. PROCEPT BioRobotics has a 1-year low of $16.67 and a 1-year high of $38.11. The company has a fifty day moving average price of $19.34 and a 200 day moving average price of $23.23. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -10.81 and a beta of 0.88.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PRCT shares. Evercore set a $23.00 price target on PROCEPT BioRobotics in a research report on Wednesday, August 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, October 15th. Piper Sandler upgraded PROCEPT BioRobotics to a “strong-buy” rating in a research report on Friday, October 16th. Wells Fargo & Company cut PROCEPT BioRobotics from an “overweight” rating to an “equal weight” rating and set a $19.00 price target for the company. in a report on Wednesday, August 5th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $20.00 price objective on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $25.50.

Insider Buying and Selling

In other PROCEPT BioRobotics news, CEO Larry Wood purchased 23,900 shares of the stock in a transaction dated Friday, August 7th. The shares were bought at an average cost of $20.85 per share, with a total value of $498,315.00. Following the completion of the acquisition, the chief executive officer owned 23,900 shares of the company’s stock, valued at approximately $498,315. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 1,043 shares of company stock valued at $21,851 over the last three months. Insiders own 4.00% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation is a medical technology company focused on developing and commercializing robotic solutions for the treatment of benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate that can cause urinary symptoms. The company’s technology is designed to provide a minimally invasive alternative to conventional surgical procedures.

Its primary product is the AquaBeam Robotic System, which uses image guidance, robotic assistance and a high-velocity waterjet to remove targeted prostate tissue.